{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Run-In+Phase&page=13", "query": { "intervention": "Run-In Phase", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 545, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Run-In+Phase&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Run-In+Phase&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T12:29:29.387Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02431208", "title": "A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2015-07-22", "completion_date": "2021-03-19", "has_results": false, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431208" }, { "nct_id": "NCT03332589", "title": "E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma", "Brain Metastases" ], "interventions": [ { "name": "E6201", "type": "DRUG" }, { "name": "E6201 plus dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spirita Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-07-02", "completion_date": "2021-10-11", "has_results": true, "last_update_posted_date": "2022-05-20", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332589" }, { "nct_id": "NCT06996782", "title": "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2025-11-24", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996782" }, { "nct_id": "NCT04105270", "title": "RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of Lung", "Lung Cancer" ], "interventions": [ { "name": "Oral Restorative Microbiota Therapy (RMT) Capsules", "type": "DRUG" }, { "name": "Durvalumab 1500 mg IV", "type": "DRUG" }, { "name": "Cisplatin/pemetrexed or Carboplatin/pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2022-11-30", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Brainerd", "state": "Minnesota" }, { "city": "Deer River", "state": "Minnesota" }, { "city": "Detroit Lakes", "state": "Minnesota" }, { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04105270" }, { "nct_id": "NCT03954704", "title": "Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Dalutrafusp alfa", "type": "DRUG" }, { "name": "mFOLFOX6 Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-06-03", "completion_date": "2021-04-15", "has_results": true, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03954704" }, { "nct_id": "NCT01839487", "title": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2013-05-14", "completion_date": "2018-09-26", "has_results": true, "last_update_posted_date": "2020-07-20", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839487" }, { "nct_id": "NCT07826949", "title": "A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent High-Grade Gliomas", "Brain Neoplasm", "Glioma" ], "interventions": [ { "name": "SRN-101", "type": "DRUG" }, { "name": "Blood Specimen Collection", "type": "PROCEDURE" }, { "name": "Surgical Resection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Nicholas Butowski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2026-10-15", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07826949" }, { "nct_id": "NCT05391022", "title": "Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies", "Solid Tumor", "Hematological Malignancy" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Constellation Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-07-20", "completion_date": "2024-02-29", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 3, "location_summary": "Canton, Ohio • Gettysburg, Pennsylvania • West Valley City, Utah", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05391022" }, { "nct_id": "NCT04431258", "title": "ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "ABTL0812", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ability Pharmaceuticals SL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2021-05-06", "completion_date": "2024-01-10", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 4, "location_summary": "Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04431258" }, { "nct_id": "NCT05363631", "title": "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma Metastatic" ], "interventions": [ { "name": "Selenomethionine (SLM)", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mohammed Milhem", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2022-09-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-10-23T12:29:29.387Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363631" } ] }